Efficacy and safety of Huazhuojiedu decoction for gastric precancerous lesions after endoscopic submucosal dissection

doi:10.4240/wjgs.122120

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 10

This Article

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article (XML)

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Surg. Oct 27, 2026; 18(10): 122120
Published online Oct 27, 2026. doi: 10.4240/wjgs.122120

Efficacy and safety of Huazhuojiedu decoction for gastric precancerous lesions after endoscopic submucosal dissection

Ying-Jie Si, Ning-Ning Ren, Jian-Yun Wang, Xin-Yu Hao, Zai-Jian Wang, Hui-Xia Li, Xue-Feng Ge, Jing An, Xiao-Shuang Shi, Tian Shen, Jie Liang, Xiao-Jing Ouyang, Xin-Yue Wang, Yan-Gang Wang

Ying-Jie Si, Ning-Ning Ren, Jian-Yun Wang, Zai-Jian Wang, Hui-Xia Li, Xue-Feng Ge, Jing An, Xiao-Shuang Shi, Tian Shen, Jie Liang, Xiao-Jing Ouyang, Xin-Yue Wang, Yan-Gang Wang, Department of Gastroenterology and Hepatology, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing 100029, China

Xin-Yu Hao, Department of Traditional Chinese Medicine, Peking University Third Hospital, Beijing 100096, China

Co-first authors: Ying-Jie Si and Ning-Ning Ren.

Author contributions: Si YJ and Ren NN are responsible for study conception, data collection, statistical analysis, and manuscript drafting; they contributed equally to this article and are co-first authors of this manuscript; Wang JY, Wang ZJ, Li HX, Ge XF, An J, Shi XS, Shen T, Liang J, Ouyang XJ, and Wang XY participated in patient recruitment and follow-up; Hao XY contributed to endoscopic coordination and pathological interpretation; Wang YG provided overall supervision and final approval; all authors approved the final manuscript.

AI contribution statement: The authors declare that no AI tools were used in the preparation of this manuscript, including study design, data collection, data analysis, interpretation of results, manuscript writing, or language editing. The authors assume full responsibility and accountability for the integrity, accuracy, originality, and scientific validity of the manuscript and all submitted materials.

Supported by National Natural Science Foundation of China, No. 82575015; Beijing Natural Science Foundation; No. 7232281; Beijing University of Chinese Medicine Project; No. 2025-JYB-JBGS-001; and Beijing University of Chinese Medicine Third Affiliated Hospital New Drug Research and Development Projects, No. 2025-YJKT-XYYF-02.

Institutional review board statement: This study was approved by the Medical Ethics Committee of the Third Affiliated Hospital of Beijing University of Chinese Medicine, approval No. ECBZRSL-ZYDSY2022-10.

Informed consent statement: The requirement for informed consent was waived by the Ethics Committee of the Third Affiliated Hospital of Beijing University of Chinese Medicine because this was a retrospective study using anonymized medical records.

Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.

STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

Data sharing statement: The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.

Corresponding author: Yan-Gang Wang, PhD, Professor, Chief Physician, Department of Gastroenterology and Hepatology, Beijing University of Chinese Medicine Third Affiliated Hospital, 2^nd Floor North Wing of the Ward Building, No. 51 Andingmenwai Xiaoguan Street, Chaoyang District, Beijing 100029, China. wangyangang1979@163.com

Received: May 22, 2026
Revised: July 28, 2026
Accepted: August 14, 2026
Published online: October 27, 2026
Processing time: 143 Days and 16.7 Hours

Core Tip

Core Tip: Huazhuojiedu decoction combined with conventional Western therapy significantly improves histopathological outcomes in patients with gastric precancerous lesions after endoscopic submucosal dissection. This study demonstrates enhanced reversal and improvement rates, enhanced gastric function (pepsinogen I, pepsinogen I/II ratio, gastrin-17), and reduced inflammatory cytokines (interleukin-6, interleukin-8, tumour necrosis factor-α). Importantly, combination therapy is associated with a lower incidence of metachronous gastric cancer and reduced progression of precancerous lesions during follow-up. These findings suggest that Huazhuojiedu decoction may exert protective effects through anti-inflammatory and multi-target regulatory mechanisms, offering a promising integrative strategy for post-endoscopic submucosal dissection management, although further randomized controlled trials are required for confirmation.